TSHA Q4 2022 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena

TSHATaysha Gene Therapies, Inc.

$1B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M

Gross Profit

$823,00032.9% margin

Operating Income

-$19M-747.4% margin

Net Income

-$56M-2227.1% margin

EPS (Diluted)

$-0.99

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

$14M

Free Cash Flow

$12M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$126M

Total Liabilities

$125M

Stockholders' Equity

$949,000

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$0	—
Gross Profit	$823,000	$0	—
Operating Income	-$19M	-$50M	+62.4%
Net Income	-$56M	-$50M	-10.6%